Mesenchymal Stromal Cells Support Endometriotic Stromal Cells<i>In Vitro</i>

Abomaray, Fawaz; Gidlöf, Sebastian; Bezubik, Bartosz; Engman, Mikael; Götherström, Cecilia

doi:10.1155/2018/7318513

Cited by 14 publications

(16 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell proliferation index was defined as the inverse of the median fluorescence intensity (MFI) of the gated proliferated population times 100. This is a slightly modified adaptation of common MFI interpretation where a lower MFI represents a higher degree of cell dye dilution and thus a higher cell proliferation index [32, 33].…”

Section: Methodsmentioning

confidence: 99%

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency

Dinh

Cameron

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Patients with primary or secondary antibody deficiency (PAD or SAD) are at increased risk of recurrent infections that can be alleviated by immunoglobulin replacement therapy (IRT). In addition to replenishing antibody levels, IRT has been suggested to modulate immune response in patients with antibody deficiency. Although both commonly treated with IRT, the underlying causes of PAD and SAD vary greatly, suggesting differential modulation of T-cell function that may lead to different responses to IRT. To explore this, peripheral blood mononuclear cells (PBMCs) were sampled from 17 PAD and 14 SAD patients before and 2–10 months after initiation of IRT, and analyzed for changes in T-cell phenotype and function. Proportions of CD4, CD8, Treg, or memory T-cells did not significantly change post-IRT compared to pre-IRT. However, we report distinct modulation in T-cell function between PAD and SAD patients post-IRT. Upon α-CD3/CD28 stimulation, proportion of IFN-γ+ CD4 and CD8 T-cells increased in SAD (p = 0.005) but not PAD patients post-IRT compared to baseline. Interestingly, total T-cell proliferation was reduced post-IRT in both PAD and SAD patients, although the reduction in proliferation was primarily due to reduced CD4 T-cell proliferation in PAD (p = 0.025) in contrast to CD8 T-cells in SAD (p = 0.042). In summary, even though IRT provides patients with passive humoral immunity-mediated protection in PAD and SAD, our findings suggest that IRT immunomodulation of T-cells is different in T-cell subsets depending on underlying immunodeficiency.

show abstract

Section: Methodsmentioning

confidence: 99%

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency

Dinh

Cameron

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Importantly, another study isolated allogeneic ADSCs from women with endometriosis to investigate their effects on endometrios isderived cells in vitro. However, they concluded that allogeneic ADSCs should not be used as a therapeutic strategy for patients with endometriosis, since they may induce the growth of ectopic endometrial tissue and support the development of endometriosis(67). Interestingly, using ADSCs along with estrogen increased endometrial regeneration in a female rat model of Asherman syndrome(68).…”

mentioning

confidence: 99%

Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

Esfandyari

Chugh

Park

et al. 2020

Preprint

View full text Add to dashboard Cite

Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency and to improve reproductive health for a significant number of women worldwide.

show abstract

“…Importantly, another study isolated allogeneic ADSCs from women with endometriosis to investigate their effects on endometriosis-derived cells in vitro. However, they concluded that allogeneic ADSCs should not be used as a therapeutic strategy for patients with endometriosis, since they may induce the growth of ectopic endometrial tissue and support the development of endometriosis [ 74 ]. Interestingly, using ADSCs along with estrogen increased endometrial regeneration in a female rat model of Asherman syndrome [ 75 ].…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

Esfandyari

Chugh

Park

et al. 2020

Cells

View full text Add to dashboard Cite

Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy, with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency, and to improve reproductive health for a significant number of women worldwide.

show abstract

Mesenchymal Stromal Cells Support Endometriotic Stromal CellsIn Vitro

Cited by 14 publications

References 40 publications

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency

Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility

Contact Info

Product

Resources

About